教員情報 - 解良　恭一 | 埼玉医科大学

教員情報トップぺージ

研究課題・受託研究・科研費

受賞履歴

学術雑誌

学会発表

専門医・専門性キーワード

（最終更新日：2025-07-29 11:22:24）

  カイラ　キョウイチ   KAIRA Kyouichi
  解良　恭一
   所属   埼玉医科大学医学部国際医療センター　呼吸器内科

職種教授

■ 研究課題・受託研究・科研費

1.	2021/03～2022/12	進行・再発非小細胞肺癌における PD-1 阻害薬と化学療法併用後のドセタキセル/ラムシルマブの効果・予後を評価するための多施設後方視研究企業からの受託研究
2.	2021/04～2023/03	肺神経内分泌腫瘍に対する免疫チェックポイント阻害剤効果予測としてのPETイメージ科学研究費　基盤研究C
3.	2022/04～2024/03	PBMCを用いたirAE発症予測システムの開発科学研究費　基盤研究C
4.	2022/04～2027/03	末梢血を用いた肺癌の免疫プレシジョンメディシン開発科学研究費　基盤研究B
5.	2022/04～2026/03	癌細胞ならびに腫瘍免疫寛容の同時制御を目指した新規治療ツール開発科学研究費　基盤研究B
6.	2023/04～2024/03	膵臓がんにおけるアミノ酸トランスポーター阻害の新規分子標的としての可能性企業からの受託研究
7.	2024/04～2027/03	肺癌術前化学免疫療法における分子イメージングの効果予測モデルの構築科学研究費　基盤研究C
8.		進行肺癌における免疫療法の効果を予測するためのPETと低酸素マーカーの可能性個人研究
5件表示
全件表示(8件)

■ 受賞履歴

1.	2007/12	群馬大学第一内科同門会賞
2.	2009/11	第47回日本肺癌学会優秀演題賞
3.	2014/06	小林がん学術振興会　先駆的研究助成
4.	2019/11	EJNMMI Best of Article award

■ 学術雑誌

1.	学術雑誌(原著)	Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. 2024/11/27
2.	学術雑誌(原著)	Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis. 2024/11/01
3.	学術雑誌(原著)	A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A. 2024/10/01
4.	学術雑誌(原著)	Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors. 2024/09/01
5.	学術雑誌(原著)	Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma. 2024/09/01
6.	学術雑誌(原著)	A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). 2024/07/07
7.	学術雑誌(症例報告)	Membranous Nephropathy as a Paraneoplastic Syndrome in Cancer of Unknown Primary. 2024/06/01
8.	学術雑誌(症例報告)	Small cell lung carcinoma initially presenting as giant left ventricular mass. 2024/05/09
9.	学術雑誌(原著)	Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study. 2024/05/01
10.	学術雑誌(症例報告)	Kaira K, Imai H, Mouri A, Yamaguchi OU, Kagamu H. 2024/05/01
11.	学術雑誌(原著)	Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab. 2024/04/03
12.	学術雑誌(原著)	Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study. 2024/04/01
13.	学術雑誌(症例報告)	Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma. 2024/03/01
14.	学術雑誌(原著)	Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051. 2024/02/15
15.	学術雑誌(原著)	Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer. Y 2024/02/01
16.	学術雑誌(症例報告)	MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer. 2024/02/01
17.	学術雑誌(原著)	Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel. 2024/02/01
18.	学術雑誌(原著)	Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L). 2024/01/27
19.	学術雑誌(原著)	Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study). 2024/01/01
20.	学術雑誌(原著)	The oncogenic role of LGR6 overexpression induced by aberrant Wnt/β-catenin signaling in lung cancer. 2024/01/01
21.	学術雑誌(原著)	Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. 2023/11/27
22.	学術雑誌(原著)	Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib. 2023/11/01
23.	学術雑誌(原著)	Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). 2023/11/01
24.	学術雑誌(原著)	Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed. 2023/09/01
25.	学術雑誌(原著)	Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. 2023/05/25
26.	学術雑誌(原著)	Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). 2023/05/01
27.	学術雑誌(症例報告)	Tumor response like pseudo-progression to lenvatinib in advanced thymic carcinoma. 2023/05
28.	学術雑誌(原著)	Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status. 2023/04/01
29.	学術雑誌(原著)	A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer. 2023/03/01
30.	学術雑誌(原著)	Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer. 2023/03/01
31.	学術雑誌(原著)	Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer. 2023/02/02
32.	学術雑誌(原著)	Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy. 2023/01/30
33.	学術雑誌(原著)	Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. 2023/01/20
34.	学術雑誌(原著)	Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study. 2022/12/30
35.	学術雑誌(原著)	A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab 2022/12/29
36.	学術雑誌(原著)	A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. 2022/12/18
37.	学術雑誌(原著)	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. 2022/12/17
38.	学術雑誌(原著)	Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. 2022/12/16
39.	学術雑誌(原著)	Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival. 2022/12/01
40.	学術雑誌(原著)	Potential of VEGFR2 expression as a predictive marker of PD‑1 blockade in patients with advanced NSCLC. 2022/12/01
41.	学術雑誌(原著)	Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 Blockade. 2022/10/01
42.	学術雑誌(原著)	Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. 2022/10/01
43.	学術雑誌(症例報告)	Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa-associated lymphoid tissue lymphoma: A case report. 2022/10/01
44.	学術雑誌(原著)	Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non-small cell lung cancer treated with intensity modulated radiotherapy. 2022/10/01
45.	学術雑誌(原著)	Identification and molecular analysis of RNF31 Q622H germline polymorphism. 2022/09/21
46.	学術雑誌(総説)	Advanced Research on Immune Checkpoint Inhibitor Therapy. 2022/09/14
47.	学術雑誌(総説)	Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment. 2022/08/20
48.	学術雑誌(原著)	A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients. 2022/08/01
49.	学術雑誌(原著)	Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). 2022/07/29
50.	学術雑誌(原著)	Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer. 2022/07/14
51.	学術雑誌(総説)	Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer. 2022/06/15
52.	学術雑誌(原著)	The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis. 2022/06/06
53.	学術雑誌(原著)	Clinical Outcomes of Postoperative Adjuvant Chemotherapy for Surgically Resected High-Grade Pulmonary Neuroendocrine Carcinoma. 2022/05/05
54.	学術雑誌(原著)	Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer. 2022/05/01
55.	学術雑誌(原著)	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer. 2022/05/01
56.	学術雑誌(原著)	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. 2022/02/17
57.	学術雑誌(原著)	Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. 2022/01/01
58.	学術雑誌(症例報告)	Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report. 2021/11
59.	学術雑誌(原著)	Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study). 2021/10/31
60.	学術雑誌(原著)	Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung. 2021/10/12
61.	学術雑誌(原著)	Insulinoma-associated protein 1 (INSM1) expression in breast carcinomas with neuroendocrine morphologies: application and future prospective 2021/07
62.	学術雑誌(症例報告)	Synchronous dilemma of sarcoid-like reaction and drastic response after PD-1 blockade administration in lung cancer. 2021/06/01
63.	学術雑誌(総説)	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. 2021/03/03
64.	学術雑誌(原著)	Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. 2021/03/01
65.	学術雑誌(原著)	A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). 2021/02/27
66.	学術雑誌(その他)	Re: INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer 2021/02
67.	学術雑誌(原著)	Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab. 2021/01/21
68.	学術雑誌(原著)	Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. 2021/01/13
69.	学術雑誌(症例報告)	Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features 2020/12
70.	学術雑誌(原著)	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma 2020/07/01
71.	学術雑誌(原著)	Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer 2020/07
72.	学術雑誌(原著)	FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer 2020/06/01
73.	学術雑誌(原著)	Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer 2020/06/01
74.	学術雑誌(原著)	Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events 2020/05/01
75.	学術雑誌(原著)	Diagnostic value of 18 F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8 + tumour-infiltrating lymphocytes in oral squamous cell carcinoma 2020/05/01
76.	学術雑誌(症例報告)	Verrucous skin lesion caused by neuropathy misdiagnosed as squamous cell carcinoma and treated with amputation surgery 2020/05/01
77.	学術雑誌(原著)	Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study 2020/04/01
78.	学術雑誌(原著)	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer 2020/04/01
79.	学術雑誌(症例報告)	Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib 2020/04/01
80.	学術雑誌(原著)	Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([ 18 F]FAMT) Uptake in Patients with Lung Cancer 2020/04/01
81.	学術雑誌(原著)	Immunological and Clinicopathological Significance of MFG-E8 Expression in Patients with Oral Squamous Cell Carcinoma 2020/04
82.	学術雑誌(原著)	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer 2020/03/07
83.	学術雑誌(原著)	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC 2020/03/01
84.	学術雑誌(症例報告)	Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review 2020/03/01
85.	学術雑誌(原著)	CD4 + T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy 2020/03
86.	学術雑誌(総説)	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients 2020/03
87.	学術雑誌(原著)	High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors 2020/03
88.	学術雑誌(原著)	Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin 2020/02/11
89.	学術雑誌(原著)	Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma 2020/02/01
90.	学術雑誌(原著)	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer 2020/02/01
91.	学術雑誌(原著)	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer 2020/02
92.	学術雑誌(原著)	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study 2020/01/25
93.	学術雑誌(原著)	Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma 2020/01
94.	学術雑誌(症例報告)	Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer 2020/01
95.	学術雑誌(症例報告)	Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab 2019/12/01
96.	学術雑誌(原著)	Save Email Send to Thorac Cancer . 2019 Dec;10(12):2200-2208. doi: 10.1111/1759-7714.13193. Epub 2019 Oct 8. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors 2019/12
97.	学術雑誌(原著)	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer 2019/10
98.	学術雑誌(原著)	Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma 2019/10
99.	学術雑誌(原著)	Fucosylated α 1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer 2019/10
100.	学術雑誌(原著)	β 2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer 2019/10
101.	学術雑誌(原著)	Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study 2019/09
102.	学術雑誌(原著)	Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death 2019/07
103.	学術雑誌(原著)	Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors 2019/07
104.	学術雑誌(原著)	Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma 2019/06
105.	学術雑誌(症例報告)	Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKI-Resistant Patients 2019/06
106.	学術雑誌(原著)	Prognostic significance and population dynamics of peripheral monocytes in patients with oropharyngeal squamous cell carcinoma 2019/06
107.	学術雑誌(症例報告)	Koga Y, Hachisu Y, Tsurumaki H, Yatomi M, Kaira K, Ohta S, Ono J, Izuhara K, Dobashi K, Hisada T. 2019/05/17
108.	学術雑誌(原著)	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer 2019/05
109.	学術雑誌(原著)	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation 2019/05
110.	学術雑誌(原著)	Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer 2019/05
111.	学術雑誌(原著)	Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer 2019/04
112.	学術雑誌(原著)	Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer 2019/04
113.	学術雑誌(原著)	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients 2019/04
114.	学術雑誌(原著)	Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer 2019/03
115.	学術雑誌(原著)	Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer 2019/03
116.	学術雑誌(原著)	Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1 2019/03
117.	学術雑誌(原著)	Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas 2019/02
118.	学術雑誌(原著)	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma 2019/02
119.	学術雑誌(症例報告)	Spontaneous aspiration of a long tree twig as foreign body 2019/02
120.	学術雑誌(症例報告)	Spontaneous aspiration of a long tree twig as foreign body. 2019/02
121.	学術雑誌(原著)	Prognostic Impact of β2 Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma 2019/01
122.	学術雑誌(原著)	Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. 1993/01/20
123.	学術雑誌(総説)	Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer. 1993/01/15
124.	学術雑誌(原著)	Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. 1993/01/01
5件表示
全件表示(124件)

■ 学会発表

1.	Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer （ポスター，一般） 2024/11
2.	EGFR 変異陽性肺癌に対するafatinib またはosimertinibを一次治療とした第2 相試験（Heat on Beat）：安全性続報. （口頭発表，一般） 2024/11
3.	肺癌周術期治療の現状と展望（口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2024/09
4.	Management and problem of oncologic emergency in advanced lung cancer （口頭発表，特別・招待講演等） 2021/11/21
5.	EGFR-TKI耐性肺癌におけるPD-1阻害剤投与後のEGFR-TKI再投与の効果（口頭発表，一般） 2021/04/25
6.	EGFR遺伝子変異陽性肺がんのEGFR-TKI治療における腫瘍内AXL発現の意義（口頭発表，一般） 2021/04/25
7.	Neuroendocrine tumor of the breast with pulmonary metastasis 30 years after mastectomy （ポスター，一般） 2020/12/07
8.	Neuroendocrine neoplasms of the breast showing peculiar forms of recurrence and/or metastasis （ポスター，一般） 2020/12/06
9.	Large cell neuroendocrine carcinoma of the breast showing triple negative, basal-like subtype （口頭発表，一般） 2020/09
5件表示
全件表示(9件)

■ 専門医・専門性キーワード

専門医取得の有無：無し
肺癌
がん薬物療法
呼吸器核医学、PET
呼吸器腫瘍病理
トランスレーショナルリサーチ